Abstract: A pharmaceutically active mycathiozole analog or salt thereof is derived from naturally occurring mycathiozole. The analog or salt is useful in cancer treatment.

Abstract: Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.

Abstract: Provided are pyrroloquinolin compounds of formula (1) or (II). In certain aspects, the pyrroloquinolin compounds are therapeutic, e.g., for treating a cell proliferative disorder. Also provided are conjugates that include the pyrroloquinolin compounds of the present disclosure. Compositions, e.g., pharmaceutical compositions, that include the pyrroloquinolin compounds and conjugates of the present disclosure are also provided. Further provided are therapeutic methods involving the administration of the pyrroloquinolin compounds, conjugates or compositions of the present disclosure. Kits that include the pyrroloquinolin compounds, conjugates or compositions are also provided.

Abstract: Compounds that are effective lipoxygenase inhibitors, and methods and pharmaceutical compositions for inhibiting lipoxygenases and for treatment of lipoxygenase-mediated conditions in humans and other subjects. The compounds, methods and pharmaceutical compositions utilize subersic terpenoids, jaspic terpenoids, igernellic terpenoids, hippospongic terpenoids, halicondric terpenoids, dictyodendric terpenoids, and/or heteronemic terpenoids, and synthetic derivatives or analogs thereof. Exemplary compounds include (−)-subersic acid, (+)-subersin, jaspaquinol, (−)-jaspic acid, igernellin, halisufate 7, and hipposulfate C and D, and derivatives thereof.

Abstract: Compounds that are effective lipoxygenase inhibitors, and methods and pharmaceutical compositions for inhibiting lipoxygenases and for treatment of lipoxygenase-mediated conditions in humans and other subjects. The compounds, methods and pharmaceutical compositions utilize subersic terpenoids, jaspic terpenoids, igernellic terpenoids, hippospongic terpenoids, halicondric terpenoids, dictyodendric terpenoids, and/or heteronemic terpenoids, and synthetic derivatives or analogs thereof. Exemplary compounds include (−)-subersic acid, (+)-subersin, jaspaquinol, (−)-jaspic acid, igernellin, halisufate 7, and hipposulfate C and D, and derivatives thereof.

Abstract: p-Sulfoxy cinnamic acid isolated from methanolic extracts of the eelgrass Zostera marina having significant antifouling aquatic properties. p-Sulfoxy cinnamic acid was synthesized in the laboratory from p-coumaric acid, and antifouling activity was identical to the natural compound in laboratory bioassays. In addition, sulfate esters of other phenolic acids showed similar antifouling activity, suggesting that the sulfate ester was responsible for the antifouling effect.

Abstract: p-sulfoxy cinnamic acid isolated from methanolic extracts of the eelgrass Zostera marina having significant antifouling aquatic properties. p-sulfoxy cinnamic acid was synthesized in the laboratory from p-coumaric acid, and antifouling activity was identical to the natural compound in laboratory bioassays. In addition, sulfate esters of other phenolic acids showed similar antifouling activity, suggesting that the sulfate ester was responsible for the antifouling effect.

Abstract: This invention is directed to novel compounds of Formula (I): ##STR1## wherein R is hydrogen or methyl, or a pharmaceutically acceptable salt thereof and pharmaceutical compositions formulated therewith. This invention is also directed to a method for treating helminthiasis and for inhibiting reverse transcriptase activity in an animal by the administration of compounds of Formula (I).

Abstract: This invention is directed to a method for treating helminthiasis which comprises administering to an animal in need thereof an anthelmintically effective amount of a compound of Formula (I): ##STR1## where R.sup.1 is hydrogen or --SR.sup.2,whereinR.sup.2 is hydrogen, --C(O)--CH.sub.3, or ##STR2## or a pharmaceutically acceptable salt thereof. This invention is also directed to a composition for treating helminthiasis in an animal which comprises a pharmaceutically acceptable excipient and an anthelmintically effective amount of a compound of Formula (I). This invention is also directed to novel compounds of Formula (I) wherein R.sup.